Topic: 2026 cost trend expectations and segment breakdown
Key points:
2025 blended cost trend came in slightly ahead of expectations at mid-4% range.
2026 guidance embeds a conservative blended trend of just over 5%, driven by potential Medicaid/exchange disenrollments and adverse selection.
By segment: 2026 Medicare Advantage trend expected slightly lower than blended; Medicaid/Commercial/Exchange trend expected slightly higher than blended.
Mgmt stance: Neutral; management assumes a modest trend uptick due to policy risk but maintains mid-single-digit control.
Q2 — Michael Hopp
Topic: 2026 EBITDA guide bridge ($250M–$280M) and quantification of key drivers
Key points:
2025 adjusted EBITDA exit: just above $205M.
Positive contributions: full-year Prospect run-rate → ~$246M; $12M–$15M annualized synergies (high single-digit contribution in 2026 due to phasing); mid-$20M from forward conversion/contract rates; $5M–$10M from expansion market improvements; tens of millions from Medicare rate vs. acuity (tailwind).
Headwinds: ~1%–1.5% negative spread on Medicaid rate/acuity; 10%–15% Medicaid disenrollments → ~negative $20M impact; mid-single-digit impact from exchange enrollment/mix; mid-single-digit impact from assuming $0 for California Hospital Quality Assurance Fund.
Range width (11% of midpoint) consistent with prior year (~10%).
Low end of range represents a stacked downside case; midpoint ($265M) reflects operating plan.
Mgmt stance: Neutral; provides detailed quantification but notes range conservatively accounts for multiple simultaneous headwinds.
Q3 — Jailendra P. Singh
Topic: 2027 MA Advance Notice impact and $350M EBITDA target confidence
Key points:
Astrana’s RAF is just over 1.0 (national average for MA); does not rely on disallowed diagnoses that drive the industry 1.53% and 3.32% headwinds.
Using revised risk model coefficients on Astrana’s HCC profiles, combined impact is significantly less than industry average; not yet quantified due to potential changes.
If Advance Notice unchanged, Astrana expects a positive 2.5%–3% rate impact for the organization, enabling margin-flat or slightly margin-dilutive 2027 even with industry headwinds.
2027 EBITDA guide ($350M) remains within range of outcomes, but much has changed since original guidance over a year ago; management will optimize for medium/long-term value.
Mgmt stance: Cautiously bullish; sees structural advantage on risk coding but refrains from reaffirming 2027 target with full confidence.
Q4 — Craig Jones
Topic: Opinion on appropriate MA effective growth rate and CMS final notice expectations
Key points:
Management believes effective growth rate should be in the high single-digit range, aligning with industry consensus (UNH, MedPAC).
Has communicated this view to CMS with actuarial analysis support.
Supports risk model changes that reduce “gamification” and make clinical efficacy/efficiency the competitive advantage.
Mgmt stance: Neutral/bullish; advocates for higher rates but remains supportive of equitable risk model reforms.
Q5 — David Michael Larsen
Topic: Prospect revenue mix (FFS vs. risk) and integration progress
Key points:
Vast majority of Prospect revenue maps to Care Partner segment (risk-bearing); only one acute care hospital in Care Delivery segment.
Approximately 10%–15% of Prospect revenue is fee-for-service (estimate, pending confirmation).
Prospect PCP retention >97% (gross retention); provider engagement is strong.
Hospital operates in a managed care setting serving both Astrana and other MCO members.
Mgmt stance: Bullish; highlights strong retention and integration progress.
Q&A Batch (6-10 of 10)
Q6 — Christian Borgmeier
Topic: AI tools tailwind for 2026 and beyond
Key points:
AI tools focus on lowering healthcare costs, not increasing reimbursement; over 100 U.S.-based data scientists, ML/AI/software engineers supporting proprietary platform.
AI automates prior authorizations (approvals via text during visit), claims adjudication, fraud/waste reduction, credentialing, eligibility.
Provider-facing AI gives real-time data, next-best-action workflows, claims/utilization data, high-risk patient insights; care teams use it for post-discharge engagement and transitions of care.
AI infrastructure expected to reduce G&A further; already achieved over 100 bps adjusted G&A improvement year-over-year.
Mgmt stance: Bullish — AI is seen as scalable, cost-reducing, and core to executing care model in expansion markets.
Q7 — Matt Shea
Topic: Care Enablement pipeline and EBITDA margins
Key points:
New client onboarded smoothly at start of 2026; pipeline remains strong but sales cycles are long due to integration complexity.
No specific late-stage deals or M&A in 2026 guidance; pipeline actively developed.
EBITDA margins for Care Enablement have been 20%–25% over recent quarters; expected to stay in that range going forward.
Mgmt stance: Neutral — pipeline active but no near-term conversions guaranteed; margin guidance stable.
Q8 — Andrew Mok
Topic: Medicaid and exchange disenrollment expectations
Key points:
Medicaid disenrollment expected ~10% (plus/minus a few percent) in 2026 guidance, with potential rate-acuity mismatch from adverse selection.
Exchange disenrollment expected in low tens of percentage decline; not yet seen but risk from higher premiums for auto-re-enrollees.
Medicaid monthly disenrollment historically 0.5%–1% per month due to redeterminations; same assumption going forward.
Mgmt stance: Cautious — actively monitoring exchange risk; Medicaid trend based on historical run-rate.
Q9 — Matthew Dale Gillmor
Topic: Prospect integration and member engagement (AWV)
Key points:
Legacy Astrana wellness visits at 80%; Prospect gaining but too early to share specific numbers.
Integration merging clinical/quality teams, using technology platform for gap-in-care identification, automatic calling, and care delivery sites.
Legacy Prospect was already successful (30+ years, profitable, high quality); combined strength expected to drive AWV and quality score growth.
Synergies expected on high end of range due to advanced integration state.
Mgmt stance: Bullish — early but confident in AWV improvement and synergy realization.
Q10 — Gene Mannheimer
Topic: Guidance seasonality and organic nature
Key points:
No planned M&A in 2026 guidance; company reserves right to evaluate opportunities and stock buybacks per capital deployment models.
Seasonality: Q3 expected to be stronger than other quarters; Q1 also guided; cadence consistent with prior years.
Mgmt stance: Neutral — guidance is organic; capital allocation flexible but not embedded in numbers.